SCHEMBL2117445

SCHEMBL2117445

Cc1ccc(S(=O)(=O)Nc2cc(-c3ccc(C#N)s3)ccc2C)o1

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PGR P06401 7/20 0.41
CCR2 P41597 4/20 0.41
HSD17B1 P14061 1/20 0.38
HSD17B2 P37059 1/20 0.38
NR3C1 P04150 1/20 0.36
AR P10275 1/20 0.36
POLB P06746 2/20 0.35
RAB9A P51151 1/20 0.35
MAPT P10636 3/20 0.34
TP53 P04637 1/20 0.34
KDM4E B2RXH2 2/20 0.34
ALDH1A1 P00352 2/20 0.34
HPGD P15428 2/20 0.34
HSP90AA1 P07900 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
LMNA P02545 1/20 0.33
TRIM24 O15164 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2119935 0.88 PGR (0.39) PGRHSD17B1HSD17B2NR3C1AR
SCHEMBL2119814 0.84 CCR2 (0.40) PGRCCR2HSD17B1HSD17B2NR3C1
SCHEMBL29498140 0.82 CYP2C9 (0.47) HSD17B1HSD17B2POLBRAB9AMAPT
SCHEMBL2120761 0.80 HSD17B1 (0.43) PGRHSD17B1HSD17B2NR3C1AR
SCHEMBL2121470 0.78 HSD17B1 (0.44) PGRHSD17B1HSD17B2NR3C1AR
SCHEMBL2119688 0.77 PRF1 (0.47) RAB9AMAPTKDM4EALDH1A1HPGD
SCHEMBL2119515 0.74 CCR9 (0.40) HSD17B1HSD17B2MAPTALDH1A1
SCHEMBL2118049 0.74 ALDH1A1 (0.40) HSD17B1HSD17B2RAB9AMAPTKDM4E
SCHEMBL2117835 0.74 MAPT (0.39) PGRHSD17B1HSD17B2MAPTTP53
SCHEMBL2119262 0.74 MAPT (0.37) PGRHSD17B1HSD17B2RAB9AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120095012-A1 TOLUIDINE SULFONAMIDES AND THEIR USE ELARA PHARMACEUTICALS GMBH (DE) 2012-04-19 US disclosed
EP-2382190-A1 TOLUIDINE SULFONAMIDES AND THEIR USE AS-INHIBITORS European Molecular Biology Laboratory (EMBL) (DE) 2011-11-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120095012-A1 TOLUIDINE SULFONAMIDES AND THEIR USE HIF1A, HIF1AN, EGLN3 PGR 1586/4885CCR2 894/4885HSD17B1 3605/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.